Non‐ST‐segment elevation ACS: does choice of antiplatelet therapy affect outcomes across troponin categories?

  • J Am Heart Assoc

  • from Sarfaroj Khan
  • Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Linear relationship was observed between increasing peak troponin and 30-mo ischaemic events in patients with non‐ST‐segment elevation acute coronary syndromes (NSTEACS).
  • Prasugrel vs clopidogrel showed no significant benefit in outcomes according to peak troponin.

Why this matters

  • Relationship between levels of troponin and outcomes among patients with NSTEMI is well-established; this is not explored in medically managed patients.
  • Study evaluated the effects of prasugrel and clopidogrel on outcomes according to troponin status.

Study design

  • 6763 medically managed patients with NSTEACS were randomly assigned to prasugrel or clopidogrel.
  • Relationship between peak troponin/upper limit of normal (ULN) ratio within 48 h of the index ACS event and 30‐mo outcomes were assessed.
  • Funding: Daiichi Sankyo Incorporated; Eli Lilly and Company.

Key results

  • Statistically significant differences in 30‐mo event rates were observed between peak troponin categories (<1×ULN, 6.2%; 1 to <3×ULN, 9.6%; 3 to <5×ULN, 10.8%; ≥5×ULN, 12.8%; P for all<.05).
  • No significant interactions were observed between peak troponin ratio and study treatment for any of the ischaemic outcomes after adjustment for confounding factors (P for all outcomes>.05).

Limitations

  • Troponin assays were not standardized.
  • Post-hoc analysis.